The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Open accessAbstract
BACKGROUND: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested. METHODS: In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease. RESULTS: Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17; P=0.41). Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (hazard ratio, 1.06; 95% CI, 0.95 to 1.19; P=0.29). Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68; P<0.001). Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo (P<0.001). There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group. CONCLUSIONS: The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In pre-dialysis CKD patients with or without diabetes higher Hgb targets, particularly in patients with poor initial Hgb responses, were also associated with increased cardiovascular risk.”
From Regulation of erythropoiesis by hypoxia-inducible factors (2013) · cites this paper as [229]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Self-citationCorrection of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Self-citationNormalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Self-citationEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1410 · Cited by 789
Booth, G. L., Kapral, M. K., Fung, K., & Tu, J. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68967-8 · Cited by 782
Research works printed but not linked: 2
- Pfeffer MA, 2005, Rev Cardiovasc Med, 3, S35
- Strippoli GF, 2006, Cochrane Database Syst Rev, 4, CD003967
Cited by
Sorted by citations
Items 901–1,000 of 1,000
How Can Erythropoeitin‐Stimulating Agent Use be Reduced in Chronic Dialysis Patients?
Kovesdy, C. P. (2013) · Seminars in Dialysis · doi:10.1111/sdi.12107 · Cited by 15
Nicola, L. D., Locatelli, F., Conte, G., & Minutolo, R. (2014) · Drugs · doi:10.1007/s40265-013-0175-3 · Cited by 15
Thamer, M., Zhang, Y., Kshirsagar, O. S., Cotter, D. J., & Kaufman, J. S. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.05.013 · Cited by 15
Heinisch, B. B., Vcelar, B. A., Kapiotis, S., Blann, A. D., Wolzt, M., Siller-Matula, J. M., & Jilma, B. (2011) · Platelets · doi:10.3109/09537104.2011.631621 · Cited by 15
Povsic, T. J., Sloane, R. J., Pieper, C. F., Pearson, M. P., Peterson, E. D., Cohen, H. J., & Morey, M. C. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glv180 · Cited by 15
Wyatt, C. M., & Drüeke, T. B. (2016) · Kidney International · doi:10.1016/j.kint.2016.08.016 · Cited by 15
SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
Toto, R. D. (2017) · The Nephron journals/Nephron journals · doi:10.1159/000450895 · Cited by 15
Self-citationGilbertson, D. T., Hu, Y., Peng, Y., Maroni, B. J., & Wetmore, J. B. (2017) · Clinical Nephrology · doi:10.5414/cn109031 · Cited by 15
Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
Diebold, M., & Kistler, A. D. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1263-8 · Cited by 15
Absorption, distribution, metabolism and excretion of molidustat in healthy participants
Lentini, S., van der Mey, D., Kern, A., Thuß, U., Kaiser, A., Matsuno, K., & Gerisch, M. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13409 · Cited by 15
Do We Store Packed Red Blood Cells under “Quasi-Diabetic” Conditions?
Livshits, L., Barshtein, G., Arbell, D., Gural, A., Levin, C., & Guizouarn, H. (2021) · Biomolecules · doi:10.3390/biom11070992 · Cited by 15
Akizawa, T., Nobori, K., Matsuda, Y., Taki, K., Hayashi, Y., Hayasaki, T., & Yamamoto, H. (2021) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13713 · Cited by 15
Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD
Au, E. H. K., Wong, G., Howard, K., Chapman, J. R., Castells, A., Roger, S. D., Bourke, M. J., Macaskill, P., Turner, R. M., Lim, W. H., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.07.011 · Cited by 15
Kleophas, W., Karaboyas, A., Li, Y., Bommer, J., Reichel, H., Walter, A., Icks, A., Rump, L. C., Pisoni, R. L., Robinson, B. M., et al. (2013) · Kidney International · doi:10.1038/ki.2013.143 · Cited by 15
Anemia e deficiência de ferro na insuficiência cardíaca
Gil, V. M., & Ferreira, J. (2013) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2013.06.003 · Cited by 15
Teehan, G. S., & Benz, R. L. (2011) · Anemia · doi:10.1155/2011/623673 · Cited by 15
Derebail, V. K., Nachman, P. H., Key, N. S., Ansede, H., Falk, R. J., Rosamond, W. D., & Kshirsagar, A. V. (2011) · Kidney International · doi:10.1038/ki.2011.247 · Cited by 15
Survival Benefits with Vitamin D Receptor Activation
Kovesdy, C. P. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02590310 · Cited by 15
The FDA's Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia
Singh, A. K. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00490110 · Cited by 15
Self-citationOf heart and kidney: a complicated love story
Gaiță, D. I., Mihăescu, A., & Schiller, A. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312462826 · Cited by 17
Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease
Taal, M. W., & Brenner, B. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10051-x · Cited by 15
Saglimbene, V. M., Palmer, S. C., Craig, J. C., Ruospo, M., Nicolucci, A., Tonelli, M. A., Johnson, D. W., Lucisano, G., Williams, G., Valentini, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172735 · Cited by 15
The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology
Lin, E., MaCurdy, T. E., & Bhattacharya, J. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040407 · Cited by 16
Bucalo, M. L., Barbieri, C., Roca, S., Titapiccolo, J. I., Romero, M. S. R., Ramos, R., Pérez, M. A., Manzano, D., Mari, F., & Molina, M. (2018) · Nefrología · doi:10.1016/j.nefro.2018.03.004 · Cited by 15
Radioisotope blood volume measurement in hemodialysis patients
Puri, I., Park, J., Modersitzki, F., & Goldfarb, D. S. (2013) · Hemodialysis International · doi:10.1111/hdi.12105 · Cited by 15
Peginesatide for the treatment of renal disease-induced anemia
Schmid, H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.780695 · Cited by 15
Comparison of Concurrent Complications of CKD by 2 Risk Categorization Systems
Inker, L. A., Tonelli, M. A., Hemmelgarn, B. R., Levitan, E. B., & Muntner, P. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.09.021 · Cited by 15
Price, E. A., Artz, A. S., Barnhart, H. X., Sapp, S. K., Chelune, G. J., Ershler, W. B., Walston, J. D., Gordeuk, V. R., Berger, N. A., Reuben, D. B., et al. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.06.003 · Cited by 15
Drug therapies to delay the progression of chronic kidney disease
Ward, F. L., Holian, J., & Murray, P. T. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-6-550 · Cited by 15
Tan, N., Liu, X., Cai, Y., Zhang, S., Jian, B., Zhou, Y., Xu, X., Ren, S., Wei, H., & Song, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s138615 · Cited by 15
Early winners and losers in dialysis center pay-for-performance
Saunders, M. R., Lee, H., & Chin, M. H. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2764-4 · Cited by 15
Pharmacotherapy of end-stage renal disease
Schmid, H., Schiffl, H., & Lederer, S. R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903544494 · Cited by 15
EPO for stroke therapy - Is there a future for further clinical development?
Minnerup, J., Wersching, H., & Schäbitz, W. (2010) · Experimental & Translational Stroke Medicine · doi:10.1186/2040-7378-2-10 · Cited by 15
Farag, Y. M. K., Blasco‐Colmenares, E., Zhao, D., Sanon, M., Güallar, E., & Finkelstein, F. O. (2023) · Kidney360 · doi:10.34067/kid.0000000000000218 · Cited by 15
Yanagita, M., Muto, S., Nishiyama, H., Ando, Y., Hirata, S., Doi, K., Fujiwara, Y., Hanafusa, N., Hatta, T., Hoshino, J., et al. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02415-0 · Cited by 14
Li, L., Fisher, M., Lau, W. L., Moradi, H., Cheung, A., Thai, G. T., Handwerker, J., & Kalantar‐Zadeh, K. (2014) · Hemodialysis International · doi:10.1111/hdi.12210 · Cited by 15
Pallet, N., Rabant, M., Legendre, C., Martinez, F., & Choukroun, G. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04287.x · Cited by 14
Mikhail, A. I. (2012) · Journal of Blood Medicine · doi:10.2147/jbm.s23270 · Cited by 14
Shah, A. P., Molnar, M. Z., Lukowsky, L. R., Zaritsky, J. J., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2012) · American Journal of Hematology · doi:10.1002/ajh.23255 · Cited by 14
Freburger, J. K., Ellis, A. R., Kshirsagar, A. V., Wang, L., & Brookhart, M. A. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-154 · Cited by 14
Pharmacological Management of Cardiorenal Syndromes
House, A. A., Haapio, M., Lassus, J. P. E., Bellomo, R., & Ronco, C. (2011) · International Journal of Nephrology · doi:10.4061/2011/630809 · Cited by 14
Jackevicius, C. A., Fan, C. S., & Warner, A. L. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.02.001 · Cited by 15
Erythropoietin and Heart Failure: The End of a Promise?
Kleijn, L., Westenbrink, B. D., & van der Meer, P. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft058 · Cited by 14
van Eps, C. L., Jeffriess, L., Haluska, B. A., Hawley, C. M., Coombes, J. S., Matsumoto, A., Jeffries, J., Johnson, D. W., Campbell, S. B., Isbel, N. M., et al. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-51 · Cited by 14
Cheng, H. W. B., Chan, K. Y., Lau, H. T., Man, C. W., Cheng, S. C., & Lam, C. (2015) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909115624653 · Cited by 14
Weinrauch, L. A., D’Elia, J. A., Finn, P. V., Lewis, E. F., Desai, A. S., Claggett, B. L., Cooper, M. E., & McGill, J. B. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.021 · Cited by 14
Self-citationBecker, K., & Jones, J. J. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0655-z · Cited by 14
Kidney Disease and Anemia in Elderly Patients
Musio, F. M. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.03.009 · Cited by 16
Lee, M., Kim, S.-H., Jhee, J. H., Kim, T. Y., Choi, H. Y., Kim, H. J., & Park, H. C. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01932-z · Cited by 14
Hypoxia-Inducible Factor-Proline Hydroxylase Inhibitor in the Treatment of Renal Anemia
Hu, X., Xie, J., & Chen, N. (2020) · Kidney Diseases · doi:10.1159/000510587 · Cited by 14
Alushi, B., Jost‐Brinkmann, F., Kastrati, A., Cassese, S., Fusaro, M., Stangl, K., Landmesser, U., Thiele, H., & Lauten, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184216 · Cited by 14
Murashima, M., Tanaka, T., Kasugai, T., Tomonari, T., Ide, A., Ono, M., Mizuno, M., Suzuki, T., & Hamano, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13717 · Cited by 14
Xiong, L., Zhang, H., Guo, Y., Song, Y., & Tao, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.795214 · Cited by 14
HIF-PHIs for Anemia Management in CKD
McCallum, W. I., & Weiner, D. E. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02440222 · Cited by 14
Singh, A. K., Causland, F. R. M., Claggett, B. L., Wanner, C., Więcek, A., Atkins, M. B., Carroll, K., Perkovic, V., McMurray, J. J. V., Wittes, J. T., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac342 · Cited by 14
Self-citationZanchi, A., Jehle, A. W., Lamine, F., Vogt, B., Czerlau, C., Bilz, S., Seeger, H., & de Seigneux, S. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40004 · Cited by 16
Muirhead, N., Keown, P. A., Churchill, D. N., Poulin-Costello, M., Gantotti, S., Lei, L., Gitlin, M. D., & Mayne, T. J. (2010) · Hemodialysis International · doi:10.1111/j.1542-4758.2010.00508.x · Cited by 14
Riscos, M. Á. G., Delgado, R. M., Seda-Guzmán, M., & Praena‐Fernández, J. M. (2012) · PubMed · doi:10.3265/nefrologia.pre2012.jan.11111 · Cited by 14
Memon, I. A., Norris, K. C., Bomback, A. S., Peralta, C. A., Li, S., Chen, S., McCullough, P. A., Whaley‐Connell, A. T., Jurkovitz, C. T., Tamura, M. K., et al. (2013) · Cardiorenal Medicine · doi:10.1159/000351229 · Cited by 14
Is Early Initiation of Dialysis Harmful?
Rivara, M. B., & Mehrotra, R. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12218 · Cited by 14
Higashijima, Y., Tanaka, T., & Nangaku, M. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.796358 · Cited by 14
Chen, T. K., Estrella, M. M., Astor, B. C., Greene, T., Wang, X., Grams, M. E., & Appel, L. J. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv037 · Cited by 14
Lu, L., Zhijian, H., Lei, L., Chen, W., & Zhimin, Z. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/824259 · Cited by 14
Birnie, K., Caskey, F. J., Ben‐Shlomo, Y., Sterne, J. A. C., Gilg, J. A., Nitsch, D., & Tomson, C. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw043 · Cited by 14
Kim, T. H., Rhee, C. M., Streja, E., Obi, Y., Brunelli, S. M., Kovesdy, C. P., & Kalantar‐Zadeh, K. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw012 · Cited by 14
Emerging drugs for the treatment of kidney disease-induced anemia
Małyszko, J., & Małyszko, J. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220537 · Cited by 14
Anemia in conventional hemodialysis: Finding the optimal treatment balance
Hasegawa, T., Koiwa, F., & Akizawa, T. (2018) · Seminars in Dialysis · doi:10.1111/sdi.12719 · Cited by 14
Drożdż, M., Weigert, A. L. L., Silva, F. L., Frazão, J. M., Alsuwaida, A., Krishnan, M., Kleophas, W., Brzόsko, S., Johansson, F. K., & Jacobson, S. H. (2019) · BMC Nephrology · doi:10.1186/s12882-018-1196-7 · Cited by 14
de Meent, D. G., Kerbusch, V., Barroso-Fernandez, B., den Adel, M., van Dijk, J., Golor, G., & Schaddelee, M. P. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.03.025 · Cited by 14
Effect of normovolemic hematocrit changes on blood pressure and flow
Bonnin, P., Vilar, J., & Levy, B. I. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.01.050 · Cited by 15
Tanaka, T., Nangaku, M., Imai, E., Tsubakihara, Y., Kamai, M., Wada, M., Asada, S., & Akizawa, T. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1632-9 · Cited by 14
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Anemia in CKD
Parfrey, P. S. (2021) · New England Journal of Medicine · doi:10.1056/nejme2117100 · Cited by 14
Self-citationReduction of costs for anemia-management drugs associated with the use of ferric citrate
Peterson, L. E., & Thomas, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s65158 · Cited by 13
Mark, P. B., Jhund, P. S., Walters, M. R., Petrie, M. C., Power, A. J., White, C., Robertson, M., Connolly, E., Anker, S. D., Bhandari, S., et al. (2021) · Kidney360 · doi:10.34067/kid.0004272021 · Cited by 13
Self-citationSong, H., Wei, C., Zhou, W.-X., Hu, H., & Wan, Q. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i11.1917 · Cited by 13
Cardiorenal syndrome in the pediatric population
Pradhan, S. K., Adnani, H., Safadi, R., Yerigeri, K., Nayak, S., Raina, R., & Sinha, R. (2022) · Annals of Pediatric Cardiology · doi:10.4103/apc.apc_50_22 · Cited by 13
Wang, Y., & Yu, X. (2024) · Kidney Diseases · doi:10.1159/000536039 · Cited by 14
Covic, A. C., & Abraham, I. L. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1042-9 · Cited by 13
Davis–Ajami, M. L., Wu, J., Downton, K. D., Ludeman, E. M., & Noxon, V. (2014) · Biologics · doi:10.2147/btt.s27578 · Cited by 13
Berns, J. S. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32833c3cc7 · Cited by 13
Alsalemi, N., & Awaisu, A. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-014-0023-x · Cited by 13
Erythropoietin and intravenous iron in PBM
Ralley, F. E. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.12.007 · Cited by 13
Management of Comorbid Conditions in Heart Failure
Nagarajan, V., & Tang, W. H. W. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.006 · Cited by 14
Is there a deleterious effect of erythropoietin in end-stage renal disease?
Singh, A. K. (2011) · Kidney International · doi:10.1038/ki.2011.190 · Cited by 13
Self-citationChand, S., Ward, D. G., Ng, Z.-Y. V., Hodson, J. A., Kirby, H., Steele, P., Rooplal, I., Bantugon, F., Iqbal, T. H., Tselepis, C., et al. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0083-y · Cited by 13
Risk Factors and Chronic Kidney Disease
Taal, M. W. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10021-1 · Cited by 13
End-of-Life Care in the Treatment of Heart Failure in Older Adults
McClung, J. A. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.02.014 · Cited by 14
The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease
Bazeley, J. W., & Wish, J. B. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.06.001 · Cited by 13
Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients
Kshirsagar, A. V., & Li, X. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.05.001 · Cited by 13
de Meent, D. G., den Adel, M., Kerbusch, V., van Dijk, J., Shibata, T., Kato, K., & Schaddelee, M. P. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1076 · Cited by 13
Zheng, X., Chen, X., Liu, T., Jiang, J., Cui, X., Zhao, Q., & Hu, P. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123274 · Cited by 13
Zhu, Y., Tang, Y., He, H., Hu, P., Sun, W., Jin, M., Wang, L., & Xu, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.919352 · Cited by 14
Ike, T., Doi, S., Nakashima, A., Sasaki, K., Ishiuchi, N., Asano, T., & Masaki, T. (2022) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00083.2022 · Cited by 13
Anemia in Chronic Renal Disease
Greenbaum, L. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_59 · Cited by 13
Locatelli, F., & Vecchio, L. D. (2023) · Kidney International · doi:10.1016/j.kint.2023.03.026 · Cited by 13
Serizawa, K., Yogo, K., Tashiro, Y., Aizawa, K., Kawasaki, R., Hirata, M., & Endo, K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.034 · Cited by 13
Anemia Management in Patients Receiving Chronic Hemodialysis
Thakuria, M., Ofsthun, N. J., Mullon, C. J. P., & Díaz-Buxó, J. A. (2011) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.00975.x · Cited by 13
Koibuchi, K., Miyagi, M., Arai, T., Aoki, T., Aikawa, A., & Sakai, K. (2015) · Nephrology · doi:10.1111/nep.12641 · Cited by 13
Correcting Anemia in Heart Failure: The Efficacy and Safety of Erythropoiesis-Stimulating Agents
Lawler, P. R., Filion, K. B., & Eisenberg, M. J. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.03.013 · Cited by 13
Ishigami, J., Onishi, T., Shikuma, S., Akita, W., Mori, Y., Asai, T., Kuwahara, M., Sasaki, S., & Tsukamoto, Y. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0659-6 · Cited by 13
Metadata
- Authors
- Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J. V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., & Toto, R.
- Affiliations
- Brigham and Women's Hospital (US)
- Hospital de Base (BR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Wisconsin–Madison (US)
- Northwestern University (US)
- Tufts University (US)
- Harvard University (US)
- Washington University in St. Louis (US)
- University of Glasgow (GB)
- University of Copenhagen (DK)
- The University of Texas Southwestern Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-11-19
- Volume
- 361
- Issue
- 21
- Pages
- 2019-2032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1998943227
- Cited by
- 2,096
- References
- 32
- Citations by year
- 2026: 62 · 2025: 66 · 2024: 65 · 2023: 94 · 2022: 92 · 2021: 128 · 2020: 121 · 2019: 111 · 2018: 90 · 2017: 108 · 2016: 125 · 2015: 122 · 2014: 163 · 2013: 174 · 2012: 175
- FWCI
- 125.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Robert Wood Johnson Foundation
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Biogen
- Louisiana Board of Regents
- Boston Scientific Corporation
- McGill University
- Celladon Corporation
- Covis Pharma
- Cytokinetics
- Servier
- Genentech
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- darbepoetin alfa, type 2 diabetes, chronic kidney disease, anemia, erythropoiesis-stimulating agents, cardiovascular events, end-stage renal disease, stroke, red blood cell transfusion, fatigue, hemoglobin target, cardiovascular risk reduction, non-dialysis patients
- MeSH terms
- Darbepoetin alfa, Aged, Anemia, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Erythropoietin, Female, Hematinics, Hemoglobins, Humans, Kidney Failure, Chronic, Male, Middle Aged, Neoplasms, Stroke, Renal Insufficiency, Chronic, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
